Article Information
History
- July 11, 2023.
Article Versions
- Version 1 (June 7, 2023 - 08:42).
- Version 2 (June 12, 2023 - 08:37).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- The OpenSAFELY Collaborative,
- Andrew D. Brown1,
- Louis Fisher1,
- Helen J. Curtis1,
- Milan Wiedemann1,
- William J. Hulme1,
- Lisa E.M. Hopcroft1,
- Christine Cunningham1,
- Victoria Speed1,
- Ruth E. Costello2,
- James B. Galloway3,
- Mark D. Russell3,
- Katie Bechman3,
- Zeyneb Kurt4,
- Richard Croker1,
- Chris Wood1,
- Alex J. Walker1,
- Andrea L. Schaffer1,
- Seb C.J. Bacon1,
- Amir Mehrkar1,
- George Hickman1,
- Chris Bates5,
- Jonathan Cockburn5,
- John Parry5,
- Frank Hester5,
- Sam Harper5,
- Ben Goldacre1 and
- Brian MacKenna1
- 1Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK
- 2London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
- 3Centre for Rheumatic Diseases, King’s College London, SE5 9RJ, UK
- 4Northumbria University, Sutherland Building, 2 Ellison Pl, Newcastle upon Tyne NE1 8ST, UK
- 5TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
- Corresponding author
Name: Andrew Brown e-mail: andrew.brown{at}phc.ox.ac.uk
Posted July 11, 2023.
OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide, and methotrexate monitoring, and factors associated with change in monitoring rate
